secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0000950170-25-015501
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharmaceuticals CFO Mark Vignola Departs; CEO Burroughs Takes Interim CFO Role
--------------------------------------------------------------------------------

- CFO Mark Vignola separated effective Feb 1, 2025; entered consulting agreement through July 2025.
- CEO Amy Burroughs assumes principal financial officer; VP Finance David Strauss named principal accounting officer, each on interim basis.
- Vignola receives $30k/month for first two months, $15k/month for next two, then hourly; equity awards continue vesting.
- Departure not due to any disagreement with company operations, policies, or practices.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017025015501/0000950170-25-015501-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017025015501/tern-20250201.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-015501

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer